Rilzabrutinib is a small molecule commercialized by Sanofi, with a leading Phase III program in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura).

Ligelizumab is a monoclonal antibody commercialized by Novartis, with a leading Phase III program in Food Allergy.

Skin cells called mast cells are key players in the inflammation and itchiness that can plague folks with these skin ailments ...

It's still early science -- studies in mice and in human cells -- but researchers are on the trail of an effective n ...

A new approach to treat rosacea and other inflammatory skin conditions could be on the horizon, according to a University of ...

A new approach to treat rosacea and other inflammatory skin conditions could be on the horizon, according to a University of Pittsburgh study ...

A new approach to treat rosacea and other inflammatory skin conditions could be on the horizon, according to a University of ...

About half of people with "chronic spontaneous urticaria," or CSU, the most common type of chronic hives, experience what ...

H.C. Wainwright analyst Emily Bodnar has maintained their neutral stance on SLRN stock, giving a Hold rating today.Pick the best stocks and ...

Derek Archila, an analyst from Wells Fargo, reiterated the Buy rating on ACELYRIN, INC. (SLRN – Research Report). The associated price target ...

"Medical Journeys" chart a path each step of the way for physicians and patients and provide continual resources and support, ...

A new approach to treat rosacea and other inflammatory skin conditions could be on the horizon, according to a University of ...